Europäische Union - Deutsch - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - immunsuppressiva - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. die behandlung der schweren, aktiven und progressiven rheumatoiden arthritis bei erwachsenen, die zuvor nicht mit methotrexat behandelt. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita reduziert die rate des fortschreitens von gelenkschäden, wie gemessen, durch die x-ray und verbessert die körperliche funktion, wenn sie in kombination mit methotrexat. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita gegeben werden kann als monotherapie im falle einer unverträglichkeit gegenüber methotrexat oder wenn die fortsetzung der behandlung mit methotrexat ungeeignet ist (für die wirksamkeit in der monotherapie siehe abschnitt 5. adalimumab wurde nicht untersucht bei patienten im alter von weniger als 2 jahren. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita reduziert die rate der progression der peripheren gelenkschäden, wie gemessen, durch die x-ray bei patienten mit polyarticular symmetrischen subtypen der erkrankung (siehe abschnitt 5. 1) und verbessert die körperliche funktion. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 und 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

animedica gmbh - all-rac-alpha-tocopherolacetat (ph.eur.), Ölige lösungen von colecalciferol, Ölige lösung von synthetischem vitamin a - emulsion - all-rac-alpha-tocopherolacetat (ph.eur.) 30.mg; Ölige lösungen von colecalciferol 2.5mg; Ölige lösung von synthetischem vitamin a 29.5mg

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

selectavet dr. otto fischer - all-rac-alpha-tocopherolacetat (ph.eur.), Ölige lösungen von colecalciferol, Ölige lösung von synthetischem vitamin a - injektionslösung - all-rac-alpha-tocopherolacetat (ph.eur.) 50.mg; Ölige lösungen von colecalciferol 200.mg; Ölige lösung von synthetischem vitamin a 117.65mg

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

swiss caps gmbh - Ölige lösung von synthetischem vitamin a - weichkapsel - Ölige lösung von synthetischem vitamin a 52.632mg

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

hans-e.lembcke - Ölige lösung von synthetischem vitamin a - injektionslösung - Ölige lösung von synthetischem vitamin a 600.mg

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanavita aktiengesellschaft & co. kg - Ölige lösung von synthetischem vitamin a - kapsel - Ölige lösung von synthetischem vitamin a 50.mg

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanavita aktiengesellschaft & co. kg - Ölige lösung von synthetischem vitamin a - kapsel - Ölige lösung von synthetischem vitamin a 25.mg

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

antistress aktiengesellschaft für gesundheitsschutz - rrr-alpha-tocopherolum - burgerstein vitamin e-kapseln 100 i.e. - rrr-a-tocopherolum 67.1 mg corresp. 100 u.i., excipiens pro capsula. - vitamin e-präparat - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

antistress aktiengesellschaft für gesundheitsschutz - rrr-alpha-tocopherolum - burgerstein vitamin e-kapseln 400 i.e. - rrr-a-tocopherolum 268.4 mg corresp. 400 u.i., excipiens pro capsula. - vitamin e-präparat - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

antistress aktiengesellschaft für gesundheitsschutz - pyridoxini hydrochloridum - burgerstein vitamin b6-tabletten - pyridoxini hydrochloridum 100 mg, excipiens pro compresso. - vitamin b6-präparat - synthetika